Daniel Zimpfer1, Martin Strueber2, Philipp Aigner3, Jan D Schmitto4, Arnt E Fiane5, Robert Larbalestier6, Steven Tsui7, Paul Jansz8, Andre Simon9, Stephan Schueler10, Francesco Moscato3, Heinrich Schima11,3. 1. Department of Surgery, Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria daniel.zimpfer@meduniwien.ac.at. 2. Spectrum Health, Grand Rapids, MI, USA. 3. Ludwig Boltzmann Cluster for Cardiovascular Research and Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria. 4. Hannover Medical School, Hannover, Germany. 5. Oslo University Hospital, Oslo, Norway. 6. Royal Perth Hospital, Perth, Australia. 7. Papworth Hospital NHS Foundation Trust, Cambridge, UK. 8. St Vincent's Clinic, Sydney, Australia. 9. Royal Brompton and Harefield Hospital, London, UK. 10. Freeman Hospital, Newcastle upon Tyne, UK. 11. Department of Surgery, Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria.
Abstract
OBJECTIVES: Ventricular blood stasis is a concern for continuous flow mechanical support devices and might contribute to the formation of thromboembolic events. The HeartWare® Ventricular Assist System (HVAD®) is equipped with the Lavare™ cycle that is a periodic speed modulation feature designed to alter flow patterns within the left ventricle and reduce areas of potential blood stasis. Here, we report in vitro and clinical findings on the effects of the Lavare cycle. METHODS: The effect of pump speed changes on the intraventricular flow field was examined with an in vitro particle image velocimetry model. The clinical impact of the Lavare cycle was evaluated through a retrospective review of the ReVOLVE study which includes 248 patients implanted with the HVAD following Conformité Européenne Mark in nine centres in Europe and Australia. Baseline characteristics, adverse event profiles and Kaplan-Meier survival estimates were stratified by patients using/not using the Lavare cycle. RESULTS: Particle image velocimetry showed increased ventricular washout with an active Lavare cycle as measured by the fluid velocities and angular dispersion parameters. With the Lavare cycle on, there was also a 22% decrease in the stagnation index compared with when the Lavare cycle was off. In the ReVOLVE registry, patients with the Lavare cycle turned on (n = 215) were supported for 497 patient-years, whereas patients who did not use the speed modulation (n = 33) were supported for 39.3 patient-years. The Lavare cycle did not significantly affect patient survival as both groups had approximately an 80% survival after 1 year. Patients using the Lavare cycle had significantly fewer rates of stroke [0.06 vs 0.20 events per patient-year (EPPY), P = 0.0008], sepsis (0.03 vs 0.15 EPPY, P = 0.0003) and right heart failure (0.03 vs 0.18 EPPY, P < 0.0001) with no difference in the transplant or recovery rates among the two cohorts. CONCLUSIONS: The Lavare cycle effectively generates ventricular washout and the adverse event profiles of ReVOLVE patients with the Lavare cycle on were better than those with the Lavare cycle off. Larger studies are warranted to verify the positive effect of the Lavare cycle and to optimize speed modulation settings, so additional clinically relevant improvements can be realized.
OBJECTIVES:Ventricular blood stasis is a concern for continuous flow mechanical support devices and might contribute to the formation of thromboembolic events. The HeartWare® Ventricular Assist System (HVAD®) is equipped with the Lavare™ cycle that is a periodic speed modulation feature designed to alter flow patterns within the left ventricle and reduce areas of potential blood stasis. Here, we report in vitro and clinical findings on the effects of the Lavare cycle. METHODS: The effect of pump speed changes on the intraventricular flow field was examined with an in vitro particle image velocimetry model. The clinical impact of the Lavare cycle was evaluated through a retrospective review of the ReVOLVE study which includes 248 patients implanted with the HVAD following Conformité Européenne Mark in nine centres in Europe and Australia. Baseline characteristics, adverse event profiles and Kaplan-Meier survival estimates were stratified by patients using/not using the Lavare cycle. RESULTS: Particle image velocimetry showed increased ventricular washout with an active Lavare cycle as measured by the fluid velocities and angular dispersion parameters. With the Lavare cycle on, there was also a 22% decrease in the stagnation index compared with when the Lavare cycle was off. In the ReVOLVE registry, patients with the Lavare cycle turned on (n = 215) were supported for 497 patient-years, whereas patients who did not use the speed modulation (n = 33) were supported for 39.3 patient-years. The Lavare cycle did not significantly affect patient survival as both groups had approximately an 80% survival after 1 year. Patients using the Lavare cycle had significantly fewer rates of stroke [0.06 vs 0.20 events per patient-year (EPPY), P = 0.0008], sepsis (0.03 vs 0.15 EPPY, P = 0.0003) and right heart failure (0.03 vs 0.18 EPPY, P < 0.0001) with no difference in the transplant or recovery rates among the two cohorts. CONCLUSIONS: The Lavare cycle effectively generates ventricular washout and the adverse event profiles of ReVOLVE patients with the Lavare cycle on were better than those with the Lavare cycle off. Larger studies are warranted to verify the positive effect of the Lavare cycle and to optimize speed modulation settings, so additional clinically relevant improvements can be realized.
Authors: Anamika Chatterjee; Christina Feldmann; Guenes Dogan; Jasmin S Hanke; Marcel Ricklefs; Ezin Deniz; Axel Haverich; Jan D Schmitto Journal: J Thorac Dis Date: 2018-06 Impact factor: 2.895
Authors: Supriya Shore; Michael J Pienta; Tessa M F Watt; Gardner Yost; Whitney A Townsend; Lourdes Cabrera; Michael D Fetters; Carol Chenoweth; Keith D Aaronson; Francis D Pagani; Donald S Likosky Journal: J Heart Lung Transplant Date: 2021-10-22 Impact factor: 13.569
Authors: Patricia P Wadowski; Barbara Steinlechner; Daniel Zimpfer; Thomas Schlöglhofer; Heinrich Schima; Martin Hülsmann; Irene M Lang; Thomas Gremmel; Renate Koppensteiner; Sonja Zehetmayer; Constantin Weikert; Joseph Pultar; Bernd Jilma Journal: Sci Rep Date: 2019-04-11 Impact factor: 4.379
Authors: P Aigner; M Schweiger; K Fraser; Y Choi; F Lemme; N Cesarovic; U Kertzscher; H Schima; M Hübler; M Granegger Journal: Ann Biomed Eng Date: 2019-11-18 Impact factor: 3.934
Authors: Mojgan Ghodrati; Thananya Khienwad; Alexander Maurer; Francesco Moscato; Francesco Zonta; Heinrich Schima; Philipp Aigner Journal: Int J Artif Organs Date: 2020-02-05 Impact factor: 1.595
Authors: Christoph Gross; Heinrich Schima; Thomas Schlöglhofer; Kamen Dimitrov; Martin Maw; Julia Riebandt; Dominik Wiedemann; Daniel Zimpfer; Francesco Moscato Journal: Artif Organs Date: 2020-03-01 Impact factor: 3.094